Eli Lilly and Company has announced significant findings from various studies at the American Diabetes Association's 85th Scientific Sessions. Key results include data from the ACHIEVE-1 Phase 3 trial, which assessed the safety and efficacy of orforglipron, an investigational small molecule GLP-1 receptor agonist, in adults with type 2 diabetes. Additionally, the QWINT-1, QWINT-3, and QWINT-4 Phase 3 trials evaluated the once-weekly insulin efsitora alfa for patients with type 2 diabetes, revealing promising outcomes. The BELIEVE Phase 2b trial explored bimagrumab, an investigational activin pathway inhibitor, both alone and in combination with semaglutide, demonstrating its potential for adults with overweight or obesity without type 2 diabetes. Research on eloralintide, an investigational amylin receptor agonist, highlighted its capability to reduce body weight and improve weight loss quality in rats, suggesting potential applications for obesity treatment. These studies underscore Lilly's commitment to advancing treatment options in cardiometabolic health.